Express Pharma

DCGI queries pharma company on its claim of FabiFlu use for COVID-19 patients with comorbidities

As per statement by the Glenmark and media reports, the DCGI had accelerated the process for clinical trials and reviews considering the pandemic situation, unmet medical conditions and unavailability of specific therapeutic management against COVID-19 for this drug